

## Australian Type 1 Diabetes Clinical Research Network

The Type 1 Diabetes Clinical Research Network is delivering research into patient lives by increasing the capacity of the Australian research system, forming strategic links with international trials and networks, supporting the next generation of researchers and building innovation and collaboration models.



<p>Patients &amp; researchers calling for more access to clinical research</p>	<p><b>\$5M</b> - JDRF awarded by Australian Government for T1DCRN</p> <p><b>20</b> stakeholders: first workshop</p> <p>First RFA released</p>	<p>RFA reviewed by international committee</p> <p>Over <b>\$3M</b> funding allocated</p> <p>3 large scale projects funded</p>	<p>First Mentored Clinician Researcher Fellowship awarded</p> <p>Over <b>\$300k</b> in conference support (2010 – 2013)</p>	<p><b>9</b> Pilot and Feasibility grants issued: over <b>\$700k</b></p> <p><b>5</b> Mentored Clinical Researcher Fellowships awarded: over <b>\$300k</b></p> <p>All funding from first \$5M committed</p> <p>Trial recruitment support</p>	<p><b>June 2014:</b> JDRF awarded further \$35M by Australian Government</p> <p>Ministerial launch of T1DCRN</p>	<p><b>\$20M+</b> funding committed</p> <p><b>11</b> international visitors attend review and symposium</p> <p>Ministerial announcement for \$14.5M large collaborative grants</p> <p><b>2</b> Career Development Awards</p> <p><b>1</b> Mentored Clinical Researcher Fellowship</p> <p>Next phase: collaboration, impact &amp; innovation (RFA2)</p>
2009	2010	2011	2012	2013	2014	2015

The principal goal of the T1DCRN is to positively impact the lives of people with type 1 diabetes through the support and promotion of clinical research.

## Progress since June 2014

### Research Support

\$14.5M awarded to five large collaborative projects; over 50 of Australia's best researchers will be supported by these grants.

11 of the most prominent T1D researchers from the US, UK, Europe and Canada convened by JDRF for Review Panel.

1300+ people to be recruited across the 5 trials.

### Research Partnerships

\$4M towards ENDIA with matching \$4M from Helmsley Charitable Trust (HCT), in their largest grant to date outside the US. ENDIA investigates environmental factors amongst 1400 pregnant women recruited across 17 clinical sites across Australia.

CRN partnered with the NIH-funded Immune Tolerance Network to bring a trial using a repurposed drug currently available for treatment of juvenile arthritis for the first time to 66 newly diagnosed children across NSW and QLD.

### Research Capacity

\$2.2M dedicated to supporting projects that will have a long-lasting impact on Australia's research capacity. Stage two for ADDN will expand the current pool of 6000 children to 10000, connect the current paediatric clinical centres with up to 5 adult sites in each State – and pilot in regional areas. It supports connection with other registries around the world.

### Research Excellence

The network is mentoring and training a new generation of researchers to become independent leaders and investigators.

\$1.9M towards two Career Development Awards providing salary support and generous start-up funding for innovative research. Also funds Mentored Clinical Researcher Fellowships to support the scientific work of practicing clinicians.

### Research Connectivity

A progressive, results-oriented meeting bringing together 43 key opinion leaders including clinicians, scientists and other T1D experts to connect, workshop issues and share ideas. This meeting resulted in a number of recommendations for enhancing T1D research productivity which will begin to be implemented in 2016.

A network-focused Symposium featuring 11 international research leaders in type 1 diabetes. This created a unique opportunity for Australian researchers to work with these global leaders on how best to enhance and utilise international collaborations that will be essential for success.

19 clinical centres to join 4 Consortia, as confirmed during 2015 Annual T1DCRN meeting with 43 clinicians, scientists and other stakeholders.

### Community

42 media mentions from 21 items. Total circulation over 1 million.

Over 80% of House of Representative MPs have a strong electorate link to a community family.

## Projects

<b>Research Support</b> Over \$14.5M   5 large, collaborative clinical studies   50 researchers supported   1,500+ patients	
<b>Professor Mark Cooper</b>	Nox inhibition in type 1 diabetic kidney disease
<b>Professor Alicia Jenkins</b>	FAME 1 Eye Study – preventing vision loss in type 1 diabetes
<b>A/Professor Elizabeth Davis</b>	Reducing blood glucose extremes caused by food and exercise in young people with type 1 diabetes
<b>Professor Timothy Jones</b> <b>A/Professor David O’Neal</b>	Assessment and translation of closed-loop insulin therapy in children, adolescents and adults with type 1 diabetes
<b>Professor Philip O’Connell</b>	Strategies for drug-free immunosuppression in islet transplantation
<b>Research Partnerships</b> Over \$4M   1,400+ patients	
<b>ENDIA</b>	JDRF leveraged additional \$4M, delivering a total of \$8M to this unique Australian multi-centre clinical trial, investigating the relationship between genes and environmental exposures during pregnancy and early-life.
<b>Immune Tolerance Network (ITN)</b> <small>Funded by the National Institutes of Health (NIH)</small>	2015: \$5M from ITN for clinical trial to slow the development of newly diagnosed type 1 diabetes in children, testing an existing drug, currently approved for use in children with juvenile arthritis.
<b>Research Capacity</b> Over \$2.2M   10,000 patients to be included	
<b>ADDN</b>	2015: over \$2M to extend and grow this national shared database capturing clinical information from type 1 diabetes patients and connecting the data on a single, purpose-built platform.
<b>Researcher Excellence</b> Over \$1.9M	
<b>A/Professor Anand Hardikar (CDA)</b>	PREDICT T1D: Plasma RNA evaluation and diagnosis in children progressing to type 1 diabetes.
<b>A/Professor Melinda Coughlan (CDA)</b>	Mapping the mitochondrial signature of individuals with type 1 diabetes and nephropathy.
<b>Dr Mary Abraham (MCRF)</b>	Mentorship by Prof Timothy Jones as part of larger program.
<b>Researcher Connectivity</b>	
<b>11 highly respected international leaders in type 1 diabetes research</b>	<ul style="list-style-type: none"> <li>- Conducted an external peer review of RFA1</li> <li>- Gave presentations at a symposium in Sydney in July 2015</li> </ul>
<b>43 key opinion leaders</b>	April 2015: Progressive, results-oriented meeting to connect, workshop issues.
<b>Research Productivity</b>	
<b>Support the more efficient and productive delivery and adoption of clinical research</b>	<ul style="list-style-type: none"> <li>- Innovative processes and components required for research success</li> <li>- Research protocols for practices outside traditional scientific research (e.g. health economics and psycho-socio measures)</li> </ul>
<b>Current RFA</b> Project funding of up to \$1.5M for a period of two to three years	
<b>RFA 2 – Innovation – now live</b> Visit <a href="http://www.t1dcrn.org.au">www.t1dcrn.org.au</a> for more info	Seeking innovative proposals describing cutting-edge innovation falling outside current type 1 diabetes research paradigms supported by collaborative teams.